TrimRx's Blog

Wegovy is not physically addictive, but psychological dependence on weight management medication differs from substance addiction. Here’s what recovery

Research shows GLP-1 agonists like Wegovy may reduce Alzheimer’s risk by up to 54% through anti-inflammatory pathways—here’s what the clinical evidence

Wegovy (semaglutide) shows emerging evidence of reducing alcohol intake in some patients through GLP-1 receptor pathways affecting reward signaling.

Wegovy doesn’t cause gambling addiction through direct neurochemical action, but GLP-1 receptor changes can unmask compulsive behaviors in predisposed

Wegovy doesn’t treat nicotine dependence — it targets GLP-1 receptors for weight loss, not addiction pathways. Here’s what the research shows.

Wegovy may trigger compulsive shopping in some patients through dopamine pathway changes. We explain the mechanism, warning signs, and what to do if it

Wegovy doesn’t directly treat social anxiety, but weight loss can improve confidence. Here’s what clinical evidence shows about GLP-1 medications and

Weight loss plateaus after three months on Mounjaro happen when metabolic adaptation outpaces GLP-1 signalling. Here’s what to adjust — and when to

Mounjaro hair loss affects 5–8% of patients during rapid weight reduction. Here’s the biological mechanism, timeline, and prevention strategies.